Illumina, Analytik Jena Partner on Ultra-High Throughput Genotyping
Analytik Jena has entered a partnership with Illumina, headquartered in San Diego. In so doing Analytik Jena gains access to the growing genotyping market currently being served by Illumina’s technologies by offering a production scale solution to provide ultra-high throughput sample preparation in support of Illumina’s enhanced 96-sample Infinium® XT BeadChip.
“This partnership further strengthens Analytik Jena’s presence in the genomics market,” said Ulrich Krauss, CEO of Analytik Jena. “We look forward to working with Illumina and their customers to deploy solutions for ultra-high throughput genotyping.”
The agreement is structured as a co-development and co-marketing partnership to provide a turnkey automated sample preparation solution for the Infinium® XT UHT protocols. The automation provided by Analytik Jena promises ultra-high throughput genotyping, scaling from several hundred thousand to 1 million samples per year. Illumina’s Infinium family of genotyping assays harnesses proven chemistry and the robust BeadChip platform to produce high data quality, call rates, and reproducibility at a low error rate. With the planned complete solution consisting of specially configured CyBio® FeliX platforms, scientists will be able to prepare up to six reaction plates (576 samples) with Infinium XT reagents for 2304 or 4608 sample BeadChip chemistries in downstream processes.
Adding complementary CyBio® FeliX platforms to the workflow leads to an increase in capacity and sample throughput, with the software allowing for a seamless transition. Simplified protocols, real-time data generation, analysis and on-demand QC reporting are a few of the newest features available for the platform, with the interactive user interface fully integrated with the next generation of Illumina LIMS.
“The CyBio® FeliX system will help our customers optimize their genotyping operations with a more cost-effective, scalable and efficient workflow for production-scale genotyping applications,” said Jason Johnson, Senior Director for Arrays at Illumina. “We were impressed with the robustness of the platform and commitment from Analytik Jena to provide our customers with an exceptional experience to continue growing their business with us.”
CRISPR Study Reveals Errors in Earlier Cancer ResearchNews
MELK, a protein previously thought to be implicated in cancer, has been shown to be unrelated to the disease.READ MORE